We therefore suggest that the VIM mRNA present in sEVs is a specific marker of more differentiated GBM cells compared to stem cells and may serve as a potential biomarker for the characterization of GBM in the body fluids of patients and/or as potential future targets in GBM therapy. Here, VIM is linked to glioblastoma.